Novartis Ag · SIX:NOVN
Novartis — Q1 2024 Earnings Presentation
76 slides from Novartis's earnings presentation, Apr 23, 2024
Slide 1: Q1 2024 Results
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q1 2024 Results Q1 2024 Results Investor presentation Investor presentation April 23, 2024 April 23, 2024 Novartis Q1 Results | April 23, 2024 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potenti
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References Company overview overview Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q1 Results | April 23, 2024 3
Slide 4: Robust double-digit sales growth and core margin expansion in Q1
Content Click below to navigate Novartis delivered robust double-digit sales growth and core margin expansion in Q1, supporting a guidance upgrade for FY through the document Company overview Financial review Sales Core1 operating income Innovation milestones USD bn, % cc1 USD bn, % cc1 Conclusions
Slide 5: Q1 growth broad-based across key brands
GROWTH Content Click below to navigate Q1 growth was broad-based, with strong contributions from Entresto®, Kesimpta®, Cosentyx® and Kisqali® through the document Company overview Financial review Q1 sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million cc Appendix 1,879 480 36
Slide 6: Entresto continued strong double-digit growth, +36% in Q1
GROWTH Content Click below to navigate Entresto® continued strong double-digit growth, +36% in Q1 through the document Company overview Financial review Sales evolution US weekly TRx1 Maintains strong momentum Conclusions USD m, % cc Total prescriptions (000) • US: +35% cc US Ex-US • Ex-US: +38% cc
Slide 7: Cosentyx grew +25% in Q1
GROWTH Content Click below to navigate Cosentyx® grew +25% in Q1, fueled by demand in core indications and strong launches through the document Company overview Financial review Sales evolution Strong growth across geographies Conclusions USD m, % cc • US: +25% cc US Ex-US • Ex-US: +24% cc Appendix
Slide 8: Kesimpta delivered +66% growth
GROWTH Content Click below to navigate Kesimpta® delivered +66% growth, with continued strong momentum in US and increasing penetration ex-US through the document Company overview Financial review Sales evolution Strong growth trajectory across all regions Conclusions USD m, % cc • >100k patients tr
Slide 9: Kisqali grew +54% in mBC
GROWTH Content Click below to navigate Kisqali® grew +54% in mBC, with leading share of new patient starts through the document Company overview Financial review Sales evolution US: +72% growth, with increasing recognition of unique profile1,2,3 Conclusions USD m, % cc • Leading share in mBC NBRx at
Slide 10: Pluvicto demonstrated strong growth of +47% in Q1
GROWTH Content Click below to navigate Pluvicto® demonstrated strong growth of +47% in Q1, driven by new patient starts in the US through the document Company overview ® Financial review Sales evolution Q1 performance Conclusions USD m, % cc • Q1 sales grew +47% cc vs. PY, driven by demand US Ex-US
Slide 11: Pluvicto PSMAfore submission-enabling OS readout achieved in Q1
INNOVATION Content Click below to navigate Pluvicto® PSMAfore submission-enabling OS readout achieved in Q1; on track to file for pre-taxane indication in H2 through the document Company overview ® Financial review Conclusions Appendix References Novartis Q1 Results | April 23, 2024 11 Novartis Q1 R
Slide 12: Leqvio adoption continued to expand across the globe
GROWTH Content Click below to navigate Leqvio® adoption continued to expand steadily across the globe through the document Company overview Financial review Sales evolution US: Continued growth outpacing advanced lipid-lowering market1 Conclusions USD m, % cc • 3,850 facilities have ordered Leqvio®
Slide 13: Scemblix grew +83% in Q1
GROWTH Content Click below to navigate Scemblix® grew +83% in Q1, driven by continued demand in 3L+ CML; 1L submission on track for H1 through the document Company overview Financial review Sales evolution Continued momentum in core indication of 3L+ CML Conclusions USD m, % cc • US: ~40%1 NBRx shar
Slide 14: Fabhalta US PNH launch showing positive early indicators
GROWTH Content Click below to navigate Fabhalta®1 US PNH launch showing positive early indicators; continue to expect modest ramp through the document Company overview Financial review Positive early launch indicators Conclusions Rapid REMS New writers and Uptake across naïve HCPs and patients Appen
Slide 15: Iptacopan Ph3 APPLAUSE-IgAN demonstrated 38% proteinuria reduction
INNOVATION Content Click below to navigate Iptacopan Ph3 APPLAUSE-IgAN study demonstrated 38%1 proteinuria reduction relative to placebo through the document Company overview Financial review Conclusions Appendix References Novartis Q1 Results | April 23, 2024 15 Novartis Q1 Results | April 23, 2024
Slide 16: Remibrutinib REMIX studies robust efficacy and safety up to 52 weeks in CSU
INNOVATION Content Click below to navigate Remibrutinib REMIX studies demonstrated robust efficacy and safety up to 52 weeks in CSU through the document Company overview Financial review High unmet need Strong efficacy3,4 with oral convenience Favorable long-term safety3,4 400,000 Significant improv
Slide 17: Expect to continue our innovation momentum in 2024
INNOVATION Content Click below to navigate Expect to continue our innovation momentum in 2024... through the document Company overview Financial review 2024 selected key events (expected) Conclusions H1 2024 H2 2024 Q1 status update Regulatory Fabhalta® PNH EU, JP CHMP positive opinion in Q1 Appendi
Slide 18: >20 key submissions in core therapeutic areas by 2028
INNOVATION Content Click below to navigate ... and to deliver >20 key submissions in core therapeutic areas by 2028 through the document Company overview Financial review Select key assets submission schedule Conclusions Core therapeutic 2024 2025 2026-2028 Appendix areas atrasentan pelacarsen2 Cose
Slide 19: Financial review and 2024 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Financial review Appendix References Financial review and 2024 guidance and 2024 guidance Harry Kirsch Harry Kirsch Chief Financial Officer Chief Financial Officer Novartis Q1 Results | April 23, 2024
Slide 20: Q1 net sales grew +11% cc with core operating income up +22% cc
FINANCIAL PROFILE Content Click below to navigate Q1 net sales grew +11% cc with core operating income up +22% cc1 through the document Company overview Financial review Continuing operations1 Q1 Q1 Change vs. PY Conclusions USD million 2024 2023 % USD % cc Appendix Net sales 11,829 10,798 10 11 Ref
Slide 21: Raising 2024 sales and core operating income guidance
FINANCIAL PROFILE Content Click below to navigate Raising 2024 sales and core operating income guidance1 Expected, barring unforeseen events; growth vs. PY in cc1 through the document Company overview Financial review Conclusions Net sales Core operating income Appendix expected to grow expected to
Slide 22: Key growth drivers support mid-term outlook of +5% sales CAGR
FINANCIAL PROFILE Content Click below to navigate Momentum in our key growth drivers strongly supports our mid-term outlook of +5% sales CAGR 2023-2028 through the document Company overview Financial review Conclusions Appendix References Novartis Q1 Results | April 23, 2024 22 Novartis Q1 Results |
Slide 23: Continuing shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy through the document Company overview Financial review Conclusions Investing in the business Returning capital to shareholders Appendix References Investments in organic business Consist
Slide 24: Expected currency impact for full year 2024
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for full year 2024 through the document Company overview Financial review Conclusions Appendix References Novartis Q1 Results | April 23, 2024 24 Novartis Q1 Results | April 23, 2024 24
Slide 25: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q1 Results | April 23, 2024 25
Slide 26: Strong start to the year, allowing us to raise FY 2024 guidance
Content Click below to navigate through the document Company overview Financial review Strong start to the year with double-digit sales growth and core margin expansion, Conclusions allowing us to raise guidance for FY 2024 Appendix References Strong momentum across all key growth brands and geograp
Slide 27: 2024 Novartis investor events
Content Click below to navigate 2024 Novartis investor events through the document Company overview Financial review Conclusions Appendix References Novartis Q1 Results | April 23, 2024 27 Novartis Q1 Results | April 23, 2024 27
Slide 28: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials References Appendix Appendix Novartis Q1 Results | April 23, 2024 28
Slide 29: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase 1/2 Phase 3 Registration Total Conclusions Oncology 24 12 3 39 Appendix Solid tumors 17 6 3 26 Innovation: Pipeline overview Hematology 7 6 0 13 Financial perform
Slide 30: Novartis pipeline in Phase 1
INNOVATION Content Click below to navigate Novartis pipeline in Phase 1 14 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis pre/post kidney tran
Slide 31: Novartis pipeline in Phase 2
INNOVATION Content Click below to navigate Novartis pipeline in Phase 2 21 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CFZ533 iscalimab CD40 inhibitor Sjögren’s Solid tumors Financial r
Slide 32: Novartis pipeline in Phase 3
INNOVATION Content Click below to navigate Novartis pipeline in Phase 3 8 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, ped
Slide 33: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration through the document Company overview Oncology Code Name Mechanism Indication(s) Solid tumors Financial review LEE011 Kisqali® CDK4/6 Inhibitor HR+/HER2- BC (adj) INC424 Jakavi® JAK1/2 inhibitor Acute GVHD, pediatrics Chron
Slide 34: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate Novartis submission schedule New Molecular Entities: Lead and supplementary indications through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions atrasentan pelacarsen ia
Slide 35: Novartis submission schedule: existing brands
INNOVATION Content Click below to navigate Novartis submission schedule Supplementary indications for existing brands through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions Lutathera® Cosentyx® Cosentyx® Aimovi
Slide 36: Net debt increased by USD 5.6bn mainly due to annual dividend
FINANCIAL PROFILE Content Click below to navigate Net debt increased by USD 5.6bn mainly due to the annual dividend payment through the document Company overview Financial review USDbn Conclusions -5.6 Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Reference
Slide 37: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience
Slide 38: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Cardiovascular, Cardiovascular, Financial performance Innovation: Clinical trials Renal and Metabolic > C ardiovascular, Renal Renal and Metabolic and Metabolic >
Slide 39: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 40: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 41: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT03955445 (CLNP023B12001B) NCT04817618 APPEAR-C3G (CLNP023B12301) Financial review Indication C3 glomerulopathy (C3G) Indication C3 glomerulopathy Phase Phase 2 Phase Phase 3 C
Slide 42: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 43: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 44: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) NCT05763875 V-Mono (CKJX839D12304) Financial review Indication CVRR (Primary prevention) Indication CVRR (Primary
Slide 45: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 46: XXB750 - NPR1 agonist
Content Click below to navigate XXB750 - NPR1 agonist XXB750 - NPR1 agonist through the document Company overview NCT05562934 (CXXB750B12201) NCT06142383 (CXXB750A12201) Financial review Indication Hypertension Indication Heart failure Phase Phase 2b Phase Phase 2 Conclusions Patients 170 Patients 7
Slide 47: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 292 Appendix Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months
Slide 48: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal Immunology and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 49: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 50: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05722522 (CAIN457O12301) NCT05758415 (CAIN457O12302) Financial review Indication Rotator cuff tendinopathy Indication Rotator cuff tendinopathy Phase Phase 3 Phase Phase
Slide 51: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT03217422 AMBER (CVAY736B2201) NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Autoimmune hepatitis Indication Lupus Nephritis Phase Phase 2 Phase Phase
Slide 52: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögren’s syndrome Indication Sjögren’s syndrome Phase Phase 3 Phase
Slide 53: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication Systemic lupus erythematosus Indication Systemic lupus erythem
Slide 54: LNA043 - ANGPTL3 agonist
Content Click below to navigate LNA043 - ANGPTL3 agonist through the document Company overview NCT04864392 ONWARDS (CLNA043A12202) Financial review Indication Knee osteoarthritis Phase Phase 2 Conclusions Patients 550 Primary Change from baseline in the cartilage thickness of the medial compartment
Slide 55: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05030311 REMIX-1 (CLOU064A2301) NCT05032157 REMIX-2 (CLOU064A2302) Financial review Indication Chronic spontaneous urticaria Indication Chronic spontaneous urticaria Pha
Slide 56: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 57: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal Neuroscience and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 58: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 180 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 59: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 60: Zolgensma - SMN1 gene replacement therapy
Content Click below to navigate Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement therapy through the document Company overview NCT05089656 STEER (COAV101B12301) NCT05386680 STRENGTH (COAV101B12302) Financial review Indication Spinal muscular atrophy (IT administration) I
Slide 61: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal Oncology and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 62: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune Thrombocytopenia Indication 2L Immune Thrombocytopenia Phase P
Slide 63: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor through the document Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating whether a patient achieves a dur
Slide 64: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants with complete TMA response wi
Slide 65: opnurasib - KRAS inhibitor
Content Click below to navigate opnurasib - KRAS inhibitor through the document Company overview NCT05132075 KontRASt-02 (CJDQ443B12301) Financial review Indication Non-small cell lung cancer, 2/3L Phase Phase 3 Conclusions Patients 360 Primary Progression free survival (PFS) Appendix Outcome Innova
Slide 66: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic castration-resistant prost
Slide 67: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 68: Scemblix - BCR-ABL inhibitor
Content Click below to navigate Scemblix® - BCR-ABL inhibitor through the document Company overview NCT04971226 ASC4FIRST (CABL001J12301) Financial review Indication Chronic myeloid leukemia, 1st line Phase Phase 3 Conclusions Patients 402 Primary Major Molecular Response (MMR) at week 48 Appendix O
Slide 69: TNO155 - SHP2 inhibitor
Content Click below to navigate TNO155 - SHP2 inhibitor through the document Company overview NCT03114319 (CTNO155X2101) Financial review Indication Solid tumors (single agent) Phase Phase 1 Conclusions Patients 255 Primary Number of participants with adverse events Appendix Outcome Number of partic
Slide 70: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and pediatri
Slide 71: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview In-market Brands In-market Brands Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal & Global Health and Metabolic > I mmu
Slide 72: Beovu - VEGF Inhibitor
Content Click below to navigate Beovu® - VEGF Inhibitor through the document Company overview NCT04278417 CONDOR (CRTH258D2301) Financial review Indication Diabetic retinopathy Phase Phase 3 Conclusions Patients 694 Primary Change from Baseline in BCVA Appendix Outcome Innovation: Pipeline overview
Slide 73: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 74: Coartem - Artemisinin combination therapy
Content Click below to navigate Coartem® - Artemisinin combination therapy through the document Company overview NCT04300309 CALINA (CCOA566B2307) Financial review Indication Malaria, uncomplicated (<5kg patients) Phase Phase 3 Conclusions Patients 44 Primary Artemether Cmax Appendix Outcome Innovat
Slide 75: ganaplacide/lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1500 Primary PCR-corrected adequa
Slide 76: References
Content Click below to navigate References through the document Entresto® (slide 6 references) Company overview 1 IQVIA National Prescription Audit. 2 AHA/ACC/HFSA/ESC. 3 Approved indications differ by geography. Examples include “indicated to reduce the risk of cardiovascular death and hospitalizat